These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1693560

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF.
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Development of new antipsychotic drugs].
    Vanden Bussche G, Gelders YG, Heylen SL.
    Acta Psiquiatr Psicol Am Lat; 1990 Feb; 36(1-2):13-25. PubMed ID: 2127339
    [Abstract] [Full Text] [Related]

  • 8. Survey on the pharmacodynamics of the new antipsychotic risperidone.
    Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE.
    Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
    [Abstract] [Full Text] [Related]

  • 9. Risperidone.
    Cohen LJ.
    Pharmacotherapy; 1994 Feb; 14(3):253-65. PubMed ID: 7524043
    [Abstract] [Full Text] [Related]

  • 10. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE, Janssen PM, Megens AA, Schotte A.
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist.
    Panocka I, Pompei P, Massi M.
    Brain Res Bull; 1993 May; 31(5):595-9. PubMed ID: 7684315
    [Abstract] [Full Text] [Related]

  • 17. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
    Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA.
    Psychopharmacology (Berl); 1993 May; 112(1 Suppl):S40-54. PubMed ID: 7530377
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.
    Roose K, Gelders Y, Heylen S.
    Acta Psychiatr Belg; 1988 May; 88(3):233-41. PubMed ID: 2466393
    [Abstract] [Full Text] [Related]

  • 20. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
    Keegan D.
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.